Genetic Determinants of 21-Hydroxylase Autoantibodies Amongst Patients of the Type 1 Diabetes Genetics Consortium | Zendy

Peter R. Baker | Zendy; P. Fain | Zendy; Heinrich Kahles | Zendy; Liping Yu | Zendy; John C. Hutton | Zendy; Janet M. Wenzlau | Zendy; Marian Rewers | Zendy; Klaus Badenhoop | Zendy; George S. Eisenbarth | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Genetic Determinants of 21-Hydroxylase Autoantibodies Amongst Patients of the Type 1 Diabetes Genetics Consortium

Author(s) -

Peter R. Baker,

P. Fain,

Heinrich Kahles,

Liping Yu,

John C. Hutton,

Janet M. Wenzlau,

Marian Rewers,

Klaus Badenhoop,

George S. Eisenbarth

Publication year - 2012

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2011-2824

Subject(s) - autoantibody , haplotype , human leukocyte antigen , major histocompatibility complex , type 1 diabetes , genotype , immunology , allele , genetics , autoimmune disease , biology , medicine , diabetes mellitus , antigen , endocrinology , gene , antibody

Autoantibodies to 21-hydroxylase (21OH-AA) precede the onset of autoimmune Addison's disease (AD) and are found in 1.5% of individuals with type 1 diabetes mellitus (T1DM). The greatest genetic risk for both disorders is found in the major histocompatibility complex (MHC), suggesting a common pathophysiology between AD and T1DM. Screening for 21OH-AA in newly diagnosed T1DM patients is a valuable prognostic tool, made stronger when MHC genotype is considered.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research